INTRODUCTION:-
Majority of drugs are frequently administered through oral route, but approximately 40% of new drug candidates have poor-water solubility and the oral delivery of such drugs is complicated for the reason that of their low bioavailability, high intra-and inter-subject variability, and not have dose linearity 1, 2 . To overcome these problems, a variety of strategies have been developed including the use of surfactants 3 , lipids 4 , permeation enhancers 4 , micronization 5 , salt formation 6 , cyclodextrins 7 , nanoparticles and solid dispersions 4, 5 etc. There has been emergent attention in the use of lipid excipients in selfemulsifying lipid formulations (SELFs) for the reason that of their capability to solubilize poorly water-soluble 'lipophilic' drugs and prevail over the problem of poor drug absorption and bioavailability 8 .
Micro emulsions and self-emulsifying systems have emerged as potential solubility enhancing technologies, whose solubilising and absorption promoting effect is thought to lay in the reactivity of triglycerides and surfactants with the walls of the gastrointestinal tract. Traditionally, long and medium-chain triglycerides (LCTs and MCTs, respectively) have been employed with surfactants to incorporate drugs into self-emulsifying systems 8 . Non-ionic surfactants, such as Tweens (polysorbates) and labrafil (poly-oxy-ethylated oleic glycerides), with high hydrophile-lipophile balances (HLB) are often used to ensure immediate formation of oil-in-water (o/w) droplets during production 9 .
Amphiphilic, non-ionic surfactants allow higher degrees of drug solubilisation to occur and may prevent the precipitation of drug out of the micro-emulsion in vivo.
Co-surfactants are frequently employed to increase the amount of drug capable of being dissolved into the lipid base, because the concentration of surfactant in most selfemulsifying systems is required to be in excess of 30 per cent w/w. These co-surfactants are often organic solvents suitable for oral administration, such as ethanol, propylene glycol and poly ethylene glycol 10 . Most self-emulsifying systems are limited to administration in lipid-filled soft or hard-shelled gelatin capsules due to the liquid nature of the product. Interaction between the capsule shell and the emulsion should be considered so as to prevent the hydroscopic contents from dehydrating or migrating into the capsule shell 11 . Atorvastatin, as a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase which catalyzes the conversion of HMG-Co A to mevalonate, an early rate-limiting step in cholesterol biosynthesis. Atorvastatin is currently used as calcium salt for the treatment of hypercholesterolemia. It is insoluble in aqueous solution of pH 4 and below; it is very slightly soluble in water and pH 7.4 phosphate buffer. The intestinal permeability of atorvastatin is high at the physiologically relevant intestinal pH. However, it is reported that the absolute bioavailability (F) of atorvastatin is 12% after a 40 mg oral dose 12 . In present study SMEDDS of Atorvastatin was prepared for enhanced solubility and dissolution of poorly soluble drug.
were procured from Qualigens Ltd., Mumbai. Tween 80, oleic acid, PEG 400, methanol (AR grade) were procured from S.D Fine chemicals, Mumbai. HPLC grade water was obtained from SD-Lab star (3TWF-UV) water purification system.
Solubility Studies:
To quantify and understand the solubility studies of atorvastatin an analytical method using RP-HPLC (Shimadzu Prominence LC-20AD was developed, optimized and validated. The solubility of atorvastatin calcium in various oils (soybean, sunflower & olive), surfactant and co-surfactants was measured using vial shake method. Unknown amount of selected vehicles was added to each cap vial containing an excess of atorvastatin , heated up to 40 o C and centrifuged (Remi RM-12C centrifuge) at 3000 rpm for 5 min. Excess insoluble atorvastatin was discarded by filtration using a membrane filter (0.45 μm, 13 mm). The concentration of atorvastatin was then quantified by RP-HPLC method (Shimadzu Prominence LC-20AD). Solubility study was performed at triplicate and standard deviation was calculated.
Preliminary screening of surfactants:-
Different surfactants for the per oral use were screened for emulsification ability. Briefly, 150 mg of each surfactant was added to 150 mg of the oily phase, heated up to 50 0 C and diluted to 100 ml with water. Ease of emulsification was judged by the number of flask inversions required to yield homogenous emulsion. Emulsions were allowed to stand for 2 hours and their percentage transmittance was evaluated by UV-Visible spectrophotometer 13 (Shimadzu, Japan). Emulsions were furthermore observed visually for any turbidity or phase separation. The selected oily phase and surfactant were used for further screening of the different co-surfactants (Brij 30 and tween 80) for their emulsification ability.
Construction of Ternary phase diagram:
The ability of oil within surfactant: co-surfactant that could self-emulsify under proper dilution can be identified and selected from ternary phase diagrams. Ternary phase diagram were constructed using water titration method. The mixture of oil with surfactant or combination of surfactant and co-surfactant were prepared in different ratios, titrated against water and agitated (Remi CM 101 DX) until slightly bluish emulsion was formed. Percentage of oil, surfactant: co-surfactant mixture and water was calculated using ternary phase diagram. CHEMEX 3.51 software tool was used to find out the emulsification zone 14 . Further the same procedure was repeated instead of oil surfactant mix to determine the effect of drug on phase diagram.
Formulation of SNEDDS:
10 mg of atorvastatin was dissolved in cosurfactant at 45˚C in an isothermal water bath. After cooling, calculated amount oil and surfactant was added and sonicated (Citizen Digital, India) until a clear solution was obtained. The formulation was equilibrated at ambient temperature for at least 48 hours to examine the signs of turbidity or phase separation. Formulations made were examined for leakage by filling in hard gelatin capsules 15 .
Table1. Various Formulations using oil: co-surfactant/surfactant ratio Characterization:
Determination of self -emulsification time:
The primary means of self-emulsification assessment is by visual evaluation. The efficiency of selfnano-emulsification is estimated by agitation at 100 rpm in mixture of water and 0.1N HCl solution (100ml) at temperature 37ºC 15 . The time required to form nanoemulsion depends upon dilution of SNEDDS with water.
Visual observation, Phase separation and stability study of emulsion:
Different formulations were diluted, agitated with 20ml of distilled water at 37˚C and allowed to stand for 24 hours. 
III
Bright white emulsion (similar to milk IV Dull, grayish white emulsion with a slightly oily appearance V Turbid appearance
Droplet size, Zeta potential and poly-dispersity analysis:
The mean droplet size, zeta potential and polydispersity index of formulations was determined by using Zeta seizer HAS 3000 (Malvern Instruments Ltd., Malvern, UK). Light scattering was monitored at 25 o C at a 90 o angle 16 . The dispersed formulations were measured after dilutions (1:100).
FTIR studies:
Infrared (IR) spectroscopy studies were conducted using FTIR (Bruker Alpha T, Germany) at 4000 to 500 cm -1 . Liquid sample preparations were made as per the instrument and the spectrum was recorded for various formulations 17 .
Physical analysis:
The surface morphology, roundness, formation of aggregates and size distribution of nano globules formed were studied by Scanning Electron Microscopy (Model: JSM-5510Jeol Ltd, Tokyo, Japan). 1gm of formulation was diluted with 10ml of pH 6.8 phosphate buffer. The nano-emulsions were mounted on an aluminum stub using double-sided carbon adhesive tape. Then the vesicles were sputter-coated with gold palladium (Au/Pd) using a vacuum evaporator and examined with digital camera, at 20kV accelerating voltage 17 .
Drug content:
Various formulations equivalent to 10 mg were taken into a standard volumetric flask, mixed and diluted with methanol. 1 ml of this solution was diluted to 10 ml with phosphate buffer pH 6.8; it gives 100µg/ml (theoretical). Further drug content was quantified using RP-HPLC method developed at 246 nm.
Cloud point measurement:
Formulations were diluted with 50 ml of water and placed on a water bath with gradually increase the temperature until the diluted formulation turned to cloudy.
It gives the information about the stability of the nanoemulsion at body temperature 18 .
In vitro release study:
Quantitative in vitro release test was performed using USP XXIV method (dissolution apparatus #2, at 50 rpm) in 900 ml 0.05M phosphate buffer at pH 6.8. SNEDDS (equivalent to 10 mg) was placed in dialysis bag to compare the release profile with conventional tablets 19 . 10 ml of sample solution was withdrawn at predetermined time intervals, filtered through a 0.45 μm membrane filter, dilute suitably and analyzed chromatographically (RP-HPLC). Equal amount of fresh dissolution medium was replaced immediately after withdrawal of the test sample. Percentage cumulative drug released at different time intervals was calculated and graph plotted versus time.
In vitro rat intestinal permeability study:
Various methods employed for intestinal permeability were modified within experimental procedures described in the literature. Male albino rats (250-300 grams) were killed by overdose with pentobarbitone IV injection. To check the intra-ileum permeability, the ileum part of intestine was isolated, washed thoroughly with cold Ringer's solution to remove the mucous and lumen contents. The formulations were diluted with 1 ml of distilled water and sample (1 mg/mL) was injected into the ileum using a syringe, making sure two sides of the intestine are tightly closed. The tissue was placed in a chamber of organ bath with continuous aeration at 37ºC. The receiver compartment was filled with 30 ml of 0.05M phosphate-buffered saline (pH 6.8). At predetermined time intervals of 15, 45, 75,105,135 and 165 minutes (up to 2.75 hours), 2 ml of the samples were withdrawn and the drug concentration was determined by validated HPLC method 20 . Percentage cumulative drug absorption of drug was calculated by plotting the graph versus time. The same procedure was repeated for marketed tablet.
Thermodynamic Stability Studies:
1. Freeze-thaw cycle:
Freeze thawing was employed to evaluate the stability of formulations. The formulations were subjected to 3 to 4 freeze-thaw cycles, which included freezing at -4°C for 48 hours followed by thawing at 40°C for 48 hours. Centrifugation was performed at 3000 rpm for 5 minutes 21 . The formulations were then observed for phase separation. Only formulations that were stable to phase separation were selected for further studies. 
Stability Studies:
The hard gelatin capsules (size 0) filled with different formulation was placed in stability chambers (REMI, India). Stability studies at 25°C/ 60% RH, 30°C/65% RH, and 40°C/75% RH were conducted according to ICH guidelines. Sampling was done at specified intervals over a period of 3 months for intermediate and accelerated conditions and 6 months for long-term conditions 21 . Drug content of the capsules was analyzed using developed RP-HPLC method.
RESULTS AND DISCUSSION:
Solubility studies: figure I . Among the various components studied oleic acid, Brij 30 and Tween 80 showed maximum solubility 9.8 ± 1.79, 73.87 ± 1.73 and 54.83 ± 0.51 mg/ml respectively. The solubility results for oil: surfactant mixtures are showed in Table 3 .
As the solubility of atorvastatin was maximum in oleic acid, Brij 30 and Tween 80 these were selected as oil and surfactant component for further development of SNEDDS. Final selection among different components would secondly be confirmed according to emulsification properties with other ingredients. Regarding surfactants and co-surfactants selection, drug solubility would come second to the main selection perspective: emulsification efficiency.
Tween 80 a non-ionic surfactant with high HLB value 15, which has miscible with atorvastatin, being less toxic and less affected by pH and ionic changes in the dispersion medium. Oleic acid was selected as oily phase because it has ability of high spontaneity for emulsification and high drug loading capacity. Brij 30 (HLB-9) was selected as cosurfactant it is a medium chain mono glyceride promotes water penetration and has good solvent capacity for drugs. showed the different areas of bluish nano emulsion (NE), slightly bluish micro emulsion (ME), and coarse emulsions (ME). It can be seen that the largest micro emulsion region is seen when the combination of surfactant and cosurfactant are used.
Ternary phase diagrams were constructed to identify the self-emulsifying regions and also to establish the optimum concentrations of oil, surfactant and co-surfactant. From the phase diagrams, it was observed that as increasing the concentration of surfactant increased the self-emulsifying region. Emulsification region decreased with increasing the concentration of co-surfactant. Efficiency of selfemulsification was good when the surfactant concentration was more than 50%. From the formulations as the concentrations of oil increases (above 35%) showed the phase separation of SNEDDS formulation. Effect of drug on phase diagram study was conducted to check the effect of emulsification region and stability of the emulsification process. Emulsification zone was narrowed as the concentration of drug increased, viscosity of the system is increased and some formulations showed gel like appearance. BF8, BF10 showed increase in the viscosity. BF16, BF18 and BF20 very viscous emulsions because the concentration of oil and surfactant concentration increases the viscosity y of the system increased, transparent emulsion was formed with increase in the concentration of concentration of Brij 30. Formulations BF1 to BF11 showed no crystal growth or no precipitation which formed micro emulsion upon dilution and was stable for 24 hours. The remaining formulations showed phase separation and precipitation. It indicates that as concentration of oil increases the stability of formulation is decreased and also increase in surfactant content the clarity is better. Table 4 . Visible assessment SNEDDS after dilution and phase separation, precipitation results on storage BF1  II  X  XX  BF2  I  X  XX  BF3  II  X  XX  BF4  I  X  XX  BF5  II  X  XX  BF6  II  X  XX  BF7  II  X  XX  BF8  II  X  XX  BF9  III  X  XX  BF10  IV  X  XX  BF11  III  X  XX  BF12  IV  +  XX  BF13  V  +  ++  BF14  V  +  ++  BF15  V  +  ++  BF16  V  +  ++  BF17  V  +  ++  BF18  V  +  ++  BF19  V  +  ++  BF20  V  + 
Formulation code Visibility grade Phase separation Precipitation

Determination of Emulsification Time:
In the study formulations (BF1-BF11) have shown spontaneity of emulsification and good stability without any signs of drug or excipient precipitation. 
Zeta potential measurement:
Zeta potential of all SNEDDS formulation was in range of -17 to -30 mV in the 50 times dilution. SNEDDS formulations consist of non-ionic components and oleic acid which show relatively negative charge. Formulations BF4 and BF6 have surface charge more than 25mv meaning will not be affected by cell membrane charge during absorption and also can produce stable nano emulsion particles. The results were similar of phenytoin. 
Thermodynamic stability study:
Thermodynamic stability study was designed to identify and avoid the metastable formulations.
The formulations were stable during centrifugation at 3500 rpm at alternative temperature cycles of 40˚c and -4˚c. There was no phase separation and precipitation observed.
FTIR Studies:
From the spectra, it is observed there is possibility of intermolecular hydrogen bonding between adjunct atorvastatin molecules. The spectrum of pure atorvastatin was equivalent to the spectra obtained by the SNEDDS indicating there were no possible incompatibilities. 
Physical Analysis of globules:
Scanning electron micrographs revealed the formation of well identified spherical globules with sharp boundaries after hydration, similar to those seen with lutein loaded novel SNEDDS. The surface characteristics of SNEDDS-derived nano emulsion are depicted in the figure 6. 
Drug content:
The drug content for the selected formulation was calculated using the standard formula. 
In-vitro release studies:
The percent cumulative release of Atorvastatin from the formulations BF4 and BF6 was found to be higher than the other formulations and marketed product (storvas ® 10 mg). The percentage drug released after 90 minutes for BF4 and BF6 were 99.65% and 89.26% were as 56.86% release for marketed product. Cumulative percent drug release is high in formulation BF4 because of low viscosity and high concentration of surfactant i.e. Tween 80. Figure 7 Percentage cumulative drug release of various formulations.
In vitro rat intestinal permeability study:
From the results it was observed that formulation BF4 has shown highest oral absorption (86.67%) thorough intestine after 165 seconds when compared to marketed product (45.34%). This may suggest absorption of the drug through the intestine increases with decreasing droplet size.
Table11 Percent cumulative drug absorbed through the rat skin 
Stability studies:
The formulations BF4 and BF6 were found to be stable for 3 months and there was no significant change in the drug content, or particle size. 
CONCLUSION:
An optimized atorvastatin loaded formulation consisting of oleic acid, Tween 80 and Brij 30 offers the advantage of good solubilisation of atorvastatin. Thus our studies confirmed that SNEDDS can be used as a possible alternative to conventional oral formulation of atorvastatin.
Results further conclude that SNEDDS can be explored as a potential drug carrier for dissolution enhancement of atorvastatin and other insoluble drugs.
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